1. ALLA AKTIER
  2. NYHETER
  3. SANIONA

Saniona

Nyheter Saniona Nyheter alla bolag

Fenja Capital II A/S requests conversion of outstanding convertibles for a total nominal amount of SEK 2 million

MARKN.

On 15 February 2024, Saniona AB (“Saniona”) issued convertibles to Fenja Capital II A/S (previously Formue Nord Fokus A/S, “Fenja Capital”) for a total nominal amount of SEK 10 million. Fenja Capital has now requested conversion of outstanding convertibles in a total nominal amount of SEK 2 million, whereby a total of 647,249 new shares are issued to Fenja Capital at a conversion price of SEK 3.09 per share.

Fenja Capital has now requested conversion of outstanding convertibles for a total nominal amount of SEK 2 million, whereby a total of 647,249 new shares are issued to Fenja Capital. In accordance with the terms and conditions for the convertibles, the conversion price amounts to SEK 3.09 per share. After the conversion, the outstanding nominal value of the convertibles will amount to SEK 8 million.

As a result of the conversion, the number of shares in Saniona will increase by 647,249, from 111,238,252 to 111,885,501. The share capital will thereby increase by SEK 32,362.45, from SEK 5,561,912.60 to SEK 5,594,275.05. Thus, the conversion entails a dilution effect of approximately 0.58 per cent of Saniona’s shares and votes.

For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona
Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona’s epilepsy pipeline features SAN711, a Phase 2-ready candidate drug targeting absence seizures, SAN2219 for acute repetitive seizures, and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine, Saniona’s most advanced candidate, is progressing towards regulatory approval for obesity in Mexico through a partnership with Medix. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona has esteemed partners, including Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market.
For more information, please visit www.saniona.com.

Attachments
Fenja Capital II A/S requests conversion of outstanding convertibles for a total nominal amount of SEK 2 million

Datum 2024-10-23, kl 08:00
Källa MFN
Bifogade filer
Fenja Capital II A/S requests conversion of outstanding convertibles for a total nominal amount of SEK 2 million
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!